TOKYO--(BUSINESS WIRE)--PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.

东京——（商业新闻短讯）——PHC控股公司（东京证交所代码：6523）（以下简称PHCHD），全球糖尿病护理公司Ascensia Diabetes Care的母公司，以及专注于为糖尿病患者开发和制造长期植入式连续血糖监测（CGM）系统的医疗技术公司Senseonics Holdings，Inc.（纽约证券交易所美国代码：SENS），今天宣布，糖尿病行业资深人士布莱恩·汉森（BrianHansen）已被任命为Ascentia糖尿病护理公司（Ascentia diabetes Care）CGM总裁的新职位，自2024年2月6日起生效。

Ascensia is the exclusive global distributor of the Eversense® E3 CGM system developed and manufactured by Senseonics..

Ascensia是Senseonics开发和制造的Eversense®E3 CGM系统的全球独家经销商。。

Mr. Hansen will be responsible for the global commercialization and growth of the innovative Eversense CGM, currently available in the U.S. and select European markets. The Eversense CGM is the industry's first and only fully implantable CGM system and allows continuous measurement of glucose levels for up to six months, compared to just one or two weeks with most CGM systems.

汉森先生将负责创新型Eversense CGM的全球商业化和增长，该CGM目前在美国和部分欧洲市场上市。Eversense CGM是业界第一个也是唯一一个完全植入式CGM系统，可以连续测量血糖水平长达六个月，而大多数CGM系统只有一到两周。

Alongside improved longevity, this next-generation system also offers people with diabetes unique and competitive features such as a removable smart transmitter1, discreet on-body vibe alerts, exceptional accuracy2, and an intuitive smartphone app..

除了延长寿命外，这一新一代系统还为糖尿病患者提供了独特且具有竞争力的功能，例如可移动的智能发射器1、谨慎的身体感应警报、异常准确2和直观的智能手机应用程序。。

Mr. Hansen previously served as Chief Commercial Officer for Tandem Diabetes Care, where he helped transform the company into a worldwide market leader, increasing patient utilization of Tandem products in the highly competitive insulin pump market. He has built a reputation for launching innovative products and overcoming commercial challenges with complex medical and regulatory landscapes.

Hansen先生曾担任Tandem Diabetes Care的首席商务官，帮助该公司转变为全球市场领导者，在竞争激烈的胰岛素泵市场中提高患者对Tandem产品的利用率。他在推出创新产品和克服复杂医疗和监管环境的商业挑战方面树立了声誉。

Previously, Mr. Hansen also held leadership positions at Adaptive Biotechnologies, Genoptix, Gen Probe, and Thermo Fisher Scientific. He holds a number of advisory board positions, including for Spotlight-AQ, Luminoah and the University of Missouri..

此前，汉森先生还在Adaptive Biotechnologies、Genoptix、Gen Probe和Thermo Fisher Scientific担任领导职务。他担任多个顾问委员会职位，包括Spotlight AQ、Luminoah和密苏里大学。。

Koichiro Sato, COO of PHCHD, known collectively with its subsidiaries as PHC Group, said, “Eversense is a game-changer for people with diabetes and is an essential part of both Ascensia’s commitment to providing high-quality and life-enhancing products and PHC Group’s global business strategy. Brian is ideally suited to lead our CGM business and enable us to realize the full potential of Eversense in the CGM market.”.

PHCHD首席运营官佐藤光一郎（KoichiroSato）及其子公司合称PHC Group，他表示，“Eversense是糖尿病患者的游戏规则改变者，是Ascensia致力于提供高质量和改善生活的产品以及PHC集团全球业务战略的重要组成部分。Brian非常适合领导我们的CGM业务，使我们能够在CGM市场上充分发挥Eversense的潜力。”。

Tim Goodnow, CEO of Senseonics, said, “We are thrilled that Ascensia has built out a dedicated CGM arm to drive patient and provider adoption of Eversense. This is a testament to our partnership and the ongoing collaboration between PHCHD, Ascensia and Senseonics. We look forward to working with Brian and leveraging his extensive industry experience to catalyze the next phase of growth for Eversense.

Senseonics首席执行官蒂姆·古德诺（TimGoodnow）表示，“我们很高兴Ascensia建立了一个专门的CGM部门，以推动患者和提供者采用Eversense。这证明了我们的合作关系以及PHCHD、Ascensia和Senseonics之间正在进行的合作。我们期待着与Brian合作，并利用他丰富的行业经验，推动Eversense的下一阶段增长。

Together our top priority will be evaluating and optimizing the strategy to deliver the benefits of Eversense to the most patients globally as we work to advance the revolutionary 365-day system to the market.”.

随着我们努力将革命性的365天系统推向市场，我们的首要任务将是评估和优化战略，为全球大多数患者提供Eversense的好处。”。

Robert Schumm, President of Ascensia, added, “Our commercialization of Eversense is building momentum as we work to drive more and more awareness of the unique benefits of Eversense. We look forward to welcoming Brian to our motivated and passionate team, and expect his wealth of experience delivering breakthrough diabetes devices will help us to unleash Eversense’s full commercial potential.”.

Ascensia总裁罗伯特·舒姆（Robert Schumm）补充道：“随着我们努力推动人们越来越多地意识到Eversense的独特优势，Eversense的商业化正在形成势头。我们期待着欢迎Brian加入我们充满活力和激情的团队，并期望他在提供突破性糖尿病设备方面的丰富经验将有助于我们释放Eversense的全部商业潜力。“。

Eversense is a key driver of Ascensia’s mission to empower people living with diabetes through solutions that simplify and improve their lives. Ascensia is also the maker of the world-renowned CONTOUR® portfolio of blood glucose monitoring (BGM) systems, available in more than 100 countries. Mr. Schumm will continue in his current role while shifting focus to the company’s BGM business..

Eversense是Ascensia通过简化和改善糖尿病患者生活的解决方案赋予糖尿病患者权力的使命的关键驱动因素。Ascensia也是全球知名的CONTOUR®血糖监测（BGM）系统组合的制造商，该系统可在100多个国家/地区使用。舒姆先生将继续担任目前的职务，同时将重点转移到公司的BGM业务上。。

Senseonics plans to provide its financial outlook for the first half of 2024 in its upcoming fourth quarter and full year 2023 earnings conference call at the end of February 2024. The full year 2024 growth outlook will be provided in the second quarter 2024 following an assessment of the current commercial plan by the new President of CGM at Ascensia Diabetes Care..

Senseonics计划在即将到来的第四季度提供2024年上半年的财务前景，并在2024年2月底举行2023年全年收益电话会议。Ascentia Diabetes Care新任总裁CGM对当前商业计划进行评估后，将于2024年第二季度提供2024年全年增长前景。。

About PHC Holdings Corporation

关于PHC控股公司

PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia, LSI Medience Corporation, Mediford Corporation, and Wemex.

PHC控股公司（TSE 6523）是一家全球医疗保健公司，其使命是通过具有积极影响并改善人们生活的医疗保健解决方案为社会健康做出贡献。其子公司包括PHC Corporation、Ascentia Diabetes Care Holdings AG、Epredia、LSI Medience Corporation、Mediford Corporation和Wemex。

Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2022 were JPY 356.4 billion with global distribution of products and services in more than 125 countries.

这些公司共同开发、制造、销售和服务糖尿病管理、医疗保健解决方案、生命科学和诊断领域的解决方案。2022财年，PHC集团的综合净销售额为3564亿日元，产品和服务在全球125多个国家分布。

www.phchd.com.

www.phchd.com.

About Senseonics

关于Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor.

Senseonics Holdings，Inc.（“Senseonics”）是一家医疗技术公司，专注于开发和制造血糖监测产品，旨在通过差异化的长期植入式血糖管理技术改变全球糖尿病社区的生活。Senseonics的CGM系统Eversense®E3包括一个完全插入皮肤下的小型传感器，该传感器与传感器上佩戴的智能变送器通信。

The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone..

葡萄糖数据每5分钟自动发送到用户智能手机上的移动应用程序。。

About Eversense

关于Eversense

The Eversense® E3 CGM System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class.

Eversense®E3 CGM系统适用于连续测量18岁及以上糖尿病患者长达180天的血糖水平。该系统用于替代用于糖尿病治疗决策的手指血糖（BG）测量。在第21天之后，当症状与CGM信息不匹配或服用四环素类药物时，仍然需要手指棒BG测量来进行校准，主要是每天一次。

The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://www.ascensiadiabetes.com/eversense/safety-info/..

传感器的插入和拆卸程序由医疗保健提供者执行。Eversense E3 CGM系统是一种处方设备；患者应该与他们的医疗保健提供者交谈以了解更多信息。有关重要的安全信息，请参阅https://www.ascensiadiabetes.com/eversense/safety-info/..

About Ascensia Diabetes Care

关于Ascensia糖尿病护理

Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Its mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives. It is home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® CGM Systems from Senseonics.

Ascentia Diabetes Care是一家全球性公司，专注于帮助糖尿病患者。它的使命是通过创新的解决方案来简化和改善糖尿病患者的生活。它拥有世界著名的CONTOUR®血糖监测系统组合，也是Senseonics Eversense®CGM系统的独家全球分销合作伙伴。

These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, it collaborates closely with healthcare professionals and other partners to ensure its products meet the highest standards of accuracy, precision and reliability, and that it conducts its business compliantly and with integrity.

这些产品将先进的技术与用户友好的功能相结合，帮助糖尿病患者管理自己的病情，并对他们的生活产生积极影响。作为糖尿病界值得信赖的合作伙伴，它与医疗保健专业人员和其他合作伙伴密切合作，确保其产品达到准确性、精确度和可靠性的最高标准，并确保其业务合规、诚信。

Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,500 employees and operations in 31 countries. For further information, please visit http://www.ascensia.com.

Ascensia是PHC集团的成员，于2016年通过PHC控股公司收购拜耳糖尿病护理公司成立。Ascensia产品销往100多个国家。Ascensia在31个国家拥有约1500名员工和业务。欲了解更多信息，请访问http://www.ascensia.com.

Forward Looking Statements

前瞻性声明

Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements regarding PHC Group’s building of its dedicated CGM business unit, statements regarding advancing a next-generation, 365-day CGM system to market, statements regarding growing the awareness, adoption, growth and potential of Eversense, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

本新闻稿中关于Senseonics未来预期、计划和前景的任何声明，包括关于PHC Group建立其专门CGM业务部门的声明，关于推进下一代365天CGM系统上市的声明，关于提高Eversense的知名度、采用率、增长率和潜力的声明，以及其他包含“相信”、“期望”、“打算”、“可能”、“项目”、“将”、“计划”和类似表述的声明，构成1995年《私人证券诉讼改革法》含义内的前瞻性声明。

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the ongoing commercialization of the Eversense product, uncertainties inherent in PHC Group’s development of a dedicated CGM business, uncertainties inherent in Ascensia’s performance and other commercial initiatives, including the ability to hire, retain and effectively incentivize the dedicated CGM workforce, uncertainties in the regulatory approval process, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration of new technology, uncertainties relating to the current economic environment and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2022, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof.

由于各种重要因素，实际结果可能与此类前瞻性声明所显示的结果存在重大差异，包括：Eversense产品持续商业化固有的不确定性，PHC集团开发专门CGM业务固有的不确定性，Ascensia业绩和其他商业举措固有的不确定性，包括雇佣、保留和有效激励专门CGM员工的能力、监管审批流程的不确定性、保险公司、监管和行政流程和决策的不确定性、新技术开发和注册的固有不确定性，与当前经济环境有关的不确定性和其他因素，详见Senseonics截至2022年12月31日的年度报告（表10-K）、截至2023年9月30日的季度报告（表10-Q）以及Senseonics在美国证券交易委员会提交的其他文件（标题为“风险因素”）中详述的风险因素。此外，本新闻稿中包含的前瞻性声明代表了Senseonics截至本文日期的观点。

Senseonics an.

Senseonics和。

1 There is no glucose data generated when the transmitter is removed.

1拆除变送器时不产生葡萄糖数据。

2 Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182

2 Garg S.等人。下一代长达180天的长期植入式Eversense连续血糖监测系统的准确性和安全性评估：PROMISE研究。糖尿病技术与治疗2021；24（2）：1-9.DOI:10.1089/dia.2021.0182